Gabapentin Capsule
Product Images NDC 70518-4411

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-4411). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
This is a description of Gabapentin Capsules, each containing 300 mg, with a total of 90 capsules in the quantity. The capsules are yellow/brown in color and should be stored at 20-25°C. The product is RX-only and has been repackaged by RemedyRepack Inc. The manufacturer is ACI Healthcare USA, Inc. from Coral Springs, FL. The usual dosage instructions are provided on an insert. Remember to keep this medication out of the reach of children.*
FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)
This formula calculates an estimated creatinine clearance rate for patients. It involves multiplying the age in years by the weight in kilograms, then dividing by 72 times the serum creatinine level in mg/dL. For female patients, an additional adjustment of multiplying by 0.85 is applied.*
FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)
This text presents data from controlled postherpetic neuralgia (PHN) studies illustrating the proportion of responders (patients with more than 50% reduction in pain score) at Endpoint. The two studies, Study 1 and Study 2, reportedly showed 32% and 14% responders respectively. The mentioned values seem to be associated with comparisons between GBP (possibly referring to gabapentin) at different dosages (3600 and 1800), PBO (possibly placebo), and GBP 2400. Detailed statistical significance information is included with p-values.*
FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.